Qishen Powder Veterinary Grade API for Tablets is processed through either direct compression or wet granulation, and the decision threshold is a Hausner ratio measured according to Ph. Eur. 2.9.36. When the tapped density of the API divided by the bulk density exceeds 1.35, direct compression is generally not viable on high-speed rotary presses because die fill variation exceeds the weight uniformity limits of USP <905> or Ph. Eur. 2.9.40. A tablet formulation for screening work includes 40–70 wt% Qishen Powder, 15–25 wt% microcrystalline cellulose, 5–10 wt% sodium starch glycolate, 3–8 wt% povidone K30, and 0.5–1.0 wt% magnesium stearate. The API is preblended with the disintegrant and silica-based glidant for 10–15 min in a bin blender at 12 rpm, followed by lubrication for 3–5 min only after the main mixing cycle is complete. Lubrication beyond 5 min or magnesium stearate above 1.0 wt% can retard disintegration because hydrophobic lubricant films form on botanical particle surfaces. The tablet press is equipped with 10 mm round, flat-faced beveled-edge tooling, precompression set to 2–4 kN, main compression between 8 kN and 14 kN, and turret speed held at 25–45 rpm. Tablet hardness should be maintained between 40 N and 70 N when measured by a constant-speed diametral crushing tester at 1.5 mm/min to avoid lamination in high-dose botanical compacts. Friability measured according to Ph. Eur. 2.9.7 must be below 1.0% after 100 drops, and disintegration via Ph. Eur. 2.9.1 should be complete within 15 min in 0.1 N hydrochloric acid at 37 °C. Published data for Qishen Powder in this exact direct compression configuration is limited; therefore the compression window is an initial process range to be verified on a compaction simulator before scaling.

Screw-fed capsule filling machines handling Qishen Powder Veterinary Grade API for Capsules are sensitive to the powder's compressibility and particle size distribution because low-density botanical powders with d50 above 150 μm create inconsistent slug formation in tamping-pin stations. Hard gelatin or hydroxypropyl methylcellulose capsules size 0 can accommodate fill weights from 300 mg to 450 mg only when the API blend is densified to a bulk density above 0.50 g/cm³ or when the blend is granulated and passed through a 0.8 mm screen mill. Direct filling of unmodified Qishen Powder often produces fill weight variability exceeding ±5% RSD at machine speeds above 30,000 capsules/h due to entrapped air and rat-holing in the hopper. A pre-fill granulation using 5 wt% polyvinylpyrrolidone binder solution and wet massing through a 1.0 mm screen, followed by fluidized-bed drying to a loss-on-drying endpoint of 2.0–4.0 wt%, reduces the Carr index from above 30% to below 20%. Capsule weight variation is assessed under Ph. Eur. 2.9.5 or USP <905>; the acceptance value for the finished product should not exceed 15.0 in L1. The blend is filled into size 0 capsules with a dosator or tamping pin machine at 20,000–40,000 capsules/h, and the finished shells are band-sealed if the package is exposed to humidity above 60% RH because the hygroscopic carbohydrate fractions in the botanical API can cross-link gelatin over time. Terminal release includes identification, assay, disintegration, loss on drying, and microbial enumeration according to Ph. Eur. 5.1.8 or USP <61>.

The following matrix aligns the seven Qishen Powder dosage forms with the compendial methods used for release and stability control.

Which Downstream Filtration Sequence Protects Qishen Powder Injectables from Subvisible Particles?

For sterile Qishen Powder Veterinary Grade API for Injections, the botanical matrix is not routed as a crude powder directly into a ready-to-use parenteral vial. The formulation is prepared as a sterile lyophilisate or sterile powder fill after extraction, filtration, and aseptic drying, because the native particle size of the raw API cannot pass terminal 0.22 μm sterilizing-grade filters without blocking. A two-stage clarification is used: a depth filtration module with a nominal retention rating of 0.8 μm followed by a 0.45 μm membrane filter and then a 0.22 μm sterilizing-grade polyethersulfone filter. Pre-filtration pressure differential should not exceed 1.0 bar; filter capacity is evaluated by Vmax testing under constant-pressure conditions. The filtered solution containing the botanical extract is filled into 10 mL or 20 mL glass vials, frozen at −40 °C to −50 °C in a lyophilizer, and dried under vacuum below 0.1 mbar with primary drying at −20 °C to 0 °C and secondary drying at 25 °C to 30 °C. Subvisible particulate matter in the reconstituted solution is controlled under USP <788>; small-volume parenteral limits are not more than 6000 particles per container at ≥10 μm and not more than 600 particles per container at ≥25 μm. Bacterial endotoxin is controlled under Ph. Eur. 2.6.14 or USP <85> with a limit consistent with the finished product dose, often not more than 0.5 EU/mg for parenteral products. The final injection is reconstituted with Water for Injection or 0.9% sodium chloride to a concentration of 50 mg/mL to 100 mg/mL before intramuscular or subcutaneous administration. Aseptic process simulation, media fill, and container closure integrity testing under USP <1207> are required because terminal moist heat sterilization is not routinely applicable if the botanical constituents undergo thermal degradation. Published data for terminal sterilization of Qishen Powder injectables is limited; aseptic lyophilisation is the default process when marker thermostability has not been established.

When Drinking Water Dispersion of Qishen Powder Drops Below 0.5% w/v

In poultry or swine drinking water systems, Qishen Powder Veterinary Grade API for Powders is formulated as a water-dispersible oral powder. The operational boundary is that the native botanical powder contains lipophilic and fibrous residue fractions that settle within 30 min when the concentration exceeds 0.5% w/v or when water hardness exceeds 250 ppm CaCO₃. To maintain a homogeneous suspension for 4–6 h, the powder is pre-mixed with sodium lauryl sulfate at 0.5–2.0 wt%, maltodextrin or glucose monohydrate at 50–80 wt%, and an antioxidant if the formula contains polyphenol-rich fractions. The blend is milled to a d90 below 75 μm using a pin mill with classifier speed set to 3000–5000 rpm. Bulk powder loss on drying is controlled at 2.0–5.0 wt% to prevent caking in aluminum foil sachets. Finished sachet powder is dissolved at 1 g/L to 2 g/L in clean water, and the resulting suspension is administered through nipple drinkers or bell drinkers. Inline mixing tanks with recirculation at 1.5 m/s maintain suspension; the outlet filter must be at least 100 μm to avoid clogging but below 500 μm to remove undispersed plant particles. Water quality is tested for pH 6.0–7.5 and total microbial load below 100 CFU/mL. The terminal oral powder is tested for uniformity of mass under Ph. Eur. 2.9.5 and for fineness by sieve analysis through a 250 μm sieve; not less than 95% should pass through the specified sieve according to the product specification.

Wet Granule Drying Endpoints, Friability Thresholds, and Sachet Stability

Qishen Powder Veterinary Grade API for Granules requires a high-shear or fluid-bed granulation step because coarser granules improve flow, reduce dust, and limit segregation during high-speed sachet filling. A vertical high-shear mixer with a 300 L bowl, 100–300 rpm impeller, 800–1500 rpm chopper, and spray nozzle for binder addition is used. The dry API, lactose monohydrate, and maize starch are dry-mixed for 5 min; 5–10 wt% povidone K30 solution in purified water is sprayed at 50–100 mL/min. The end-point of granulation is determined by impeller power consumption curve rather than fixed time; the target moisture after granulation is 12–16 wt%, and the granules are discharged through a 4 mm mesh into a fluid-bed dryer. Drying is performed at inlet air temperature 50–60 °C until loss on drying reaches 2.0–4.0 wt%; the exhaust air humidity should remain below 30% RH. Dried granules are milled through a 1.2 mm screen and the 0.15–0.85 mm fraction is collected. Granule friability is measured by placing 20 g of granules with 200 stainless steel beads in a Roche friabilator at 25 rpm for 15 min; the fraction retained on a 0.18 mm screen should be above 90% to avoid excessive fines. The finished granules are filled into 10 g or 20 g sachets at speeds of 60–120 sachets/min; fill weight relative standard deviation should be below 2.0%. Stability of the hygroscopic botanical granules in aluminum-polyethylene sachets is evaluated under ICH Q1A conditions at 40 °C/75% RH for 6 months, with sachet moisture uptake specified not to exceed 1.0%.

Ribbon Compaction and Twin-Shaft Paddle Mixing Determine Premix Homogeneity in Feed

In feed milling operations, Qishen Powder Veterinary Grade API for Premix is diluted into a carrier system before being mixed into complete feed at 0.5–5 kg per tonne. The first process step is size reduction of the botanical API to a d90 below 150 μm using a centrifugal mill with a 0.5 mm sieve ring, followed by ribbon compaction of a pre-blend containing 40 wt% API, 55 wt% defatted rice bran or wheat middlings, and 5 wt% silica dioxide. The roller compactor is set to a roll gap of 0.8–1.5 mm, hydraulic pressure of 80–120 bar, and roll speed of 5–10 rpm; the aim is to bind the fine particles into granules with bulk density above 0.60 g/cm³. Ribbon milling through a 1.0 mm screen produces a granule fraction with minimal segregation potential. The concentrated premix is then blended in a twin-shaft paddle mixer with a 2:1 ingredient-to-carrier ratio for 10–15 min at 60 rpm. Homogeneity is verified by sampling 10 points with a sample thief under ISO 6497:2002 or the applicable national code; the coefficient of variation of the active marker should be below 5.0% in the premix and below 10.0% in the complete feed. The terminal premix is packed in multi-wall paper bags with a moisture barrier liner and stored below 25 °C and below 60% RH; oil-based carriers are not recommended because lipophilic compounds in the botanical API can promote caking and microbial growth.

Oral liquid dosing with Qishen Powder Veterinary Grade API for Solutions is processed as an aqueous extract rather than as a simple dissolution of the crude powder. Extraction is performed with purified water at 60–80 °C for 2–4 h, using a solid-to-liquid ratio of 1:10 to 1:20, followed by clarification through a 200 μm filter and then a 0.45 μm membrane filter. The final oral solution contains 10–25% w/v dry extract equivalent, 10–15 wt% sorbitol, 0.1–0.3 wt% potassium sorbate, 0.05–0.2 wt% citric acid to adjust pH to 4.0–5.0, and purified water to volume. The pH range is selected to reduce microbial proliferation and to stabilize polyphenolic fractions; above pH 6.0 oxidation of phenolic marker constituents accelerates. The solution is filled into 100 mL, 500 mL, or 1 L high-density polyethylene bottles under nitrogen flushing to reduce headspace oxygen below 2.0% v/v. A 0.2 μm inline filtration step is used before filling; the finished liquid is tested for clarity, pH, density, and preservative content. Sedimentation and haze after storage at 25 °C/60% RH for 3 months indicate that the extraction yield should be reduced or the filtration step tightened to 0.2 μm. Oral solution administration rates for swine or poultry are usually 0.5–1.0 mL per kg body weight per day; the terminal product must meet microbial enumeration limits for non-sterile oral liquids under Ph. Eur. 5.1.8 or USP <61>, with total aerobic microbial count not exceeding 10² CFU/mL for non-sterile oral solutions.